Literatur
-
1
Felmingham D, Reinert R R, Hirakata Y, Rodloff A.
Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin.
J Antimicrob Chemother.
2002;
50
25-37
(Suppl S1)
-
2
File T, Segreti J, Dunbar L. et al .
A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.
Antimicrob Agents Chemother.
1997;
41
1965-1972
-
3
Finch R, Schurmann D, Collins O. et al .
Randomized Controlled Trial of Sequential Intravenous (i. v.) and Oral Moxifloxacin Compared with Sequential i. v. and Oral Co-Amoxiclav with or without Clarithromycin in Patients with Community-Acquired Pneumonia Requiring Initial Parenteral Treatment.
Antimicrob Agents Chemother.
2002;
46
1746-1754
-
4
O’Doherty B, Dutchman D, Pettit R, Maroli A.
Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia.
J Antimicrob Chemother.
1997;
40
73-81
-
5
Ortqvist A, Valtonen M, Cars O, Wahl M, Saikku P, Jean C. The Scandinavian Sparfloxacin Study Group .
Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin.
Chest.
1996;
110
1499-1506
-
6
Reinert R R, Al-Lahham A, Lemperle M. et al .
Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany.
J Antimicrob Chemother.
2002;
49
61-68
-
7
Reinert R R, Simic S, Al-Lahham A, Reinert S, Lemperle M, Lutticken R.
Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients with respiratory tract infections in Germany from 1998 to 1999: results of a national surveillance study.
J Clin Microbiol.
2001;
39
1187-1189
-
8
Tremolieres F, de Kock F, Pluck N, Daniel R.
Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia.
Eur J Clin Microbiol Infect Dis.
1998;
17
447-453
-
9
Zhanel G G, Ennis K, Vercaigne L. et al .
A critical review of the fluoroquinolones: focus on respiratory infections.
Drugs.
2002;
62
13-59
-
10
Zhanel G G, Noreddin A M.
Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections.
Curr Opin Pharmacol.
2001;
1
459-463
-
11
Zhanel G G, Walters M, Laing N, Hoban D J.
In vitro pharmacodynamic modelling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae.
J Antimicrob Chemother.
2001;
47
435-440
Dr. med. Stefan Zimmerli
Institut für Infektionskrankheiten, Universität Bern
Postfach 61
CH-3010 Bern
Phone: ++41/31/6323258
Fax: ++41/31/6323550
Email: stefan.zimmerli@ifik.unibe.ch
